The trickle down of the Affordable Care Act may make an impact in Massachusetts.

The Boston Business Journal explained how cost pressures under Obamacare can be a boon to the biotech industry in the Bay State.

Don Seiffert, a BBJ editor, said some venture capitalists see this as an opportunity.

"If you can make the argument that your drug or diagnostic is saving the whole health care system money in the end, then you can make a really compelling argument as to why your drug should be approved and be reimbursed," he said.